M6P receptor Inhibitors
2 drugsAbout M6P receptor
The Mannose-6-Phosphate receptor (M6P receptor) is a transmembrane glycoprotein that transports lysosomal enzymes within the cell. It binds to proteins tagged with mannose-6-phosphate (M6P), escorting them from the Golgi apparatus to lysosomes for degradation and recycling.
M6P receptor's role in lysosomal enzyme transport makes it a potential drug target, as disruptions can lead to lysosomal storage disorders. Currently, there is no genetic evidence directly linking M6P receptor mutations to specific diseases.
Two FDA-approved biologic drugs, POMBILITI and NEXVIAZYME, target the M6P receptor. These drugs, developed by AMICUS THERAP US and Sanofi respectively, highlight the feasibility of targeting the M6P receptor.
Top M6P receptor Drugs
The competitive landscape is limited to two companies, AMICUS THERAP US and Sanofi.
Low market concentration suggests relatively low barriers to entry for new competitors.
M6P receptor Drug Modality Landscape
Modalities
Routes of Administration
M6P receptor requires biologic approaches (enzyme), likely due to its structure or location.
The lack of small molecule or antibody drugs indicates a whitespace opportunity for novel modalities.
M6P receptor Clinical Trials 10 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on M6P receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 2 | 1 | 0 | 1 | 100% |
| Phase 3 | 5 | 2 | 0 | 3 | 100% |
| Phase 4 | 3 | 0 | 0 | 3 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
M6P receptor Drug Approval Timeline (2021 - 2023)
The first drug was approved in 2021, with the most recent approval in 2023, spanning a 3-year period.
Recent approvals suggest growing interest, but short timeline indicates early market stage.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 4 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on M6P receptor. A trial counts if an approved drug acting on M6P receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.